Hardware Steam Machine will play the majority of Steam titles 'at 4K 60 fps with FSR', but some will require more upscaling than others, Valve says FPS Valve veteran imperiously scorns reports that it ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. 1Password, one of the best password managers we've seen, is introducing Unified Access to its ...

Monday - Friday, 6:00 - 7:00 PM ET In a Monday interview with CNBC's Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the pharmaceutical giant's new pill format of its weight loss drug will allow ...

Abstract: Distributed optimization provides a framework for deriving distributed algorithms for a variety of multi-robot problems. This tutorial constitutes the first part of a two-part series on ...

The Suzuki e-Access has a claimed range of just 95km on a single full charge. Suzuki starts bookings for its first electric scooter, e-Access, priced at Rs 1,88,490. e-Access has a 3.07kWh LFP battery ...

Suzuki has finally launched the e-Access electric scooter in India at a surprising price of Rs 1,88,490 (ex-showroom, Delhi). Bookings are now open across all authorised Suzuki dealerships in the ...

BENGALURU: Space engineering firm Dhruva Space Thursday announced Polar Access-1 (PA-1), its most integrated launch programme so far, under which it will support 10 space missions serving multiple ...

Novo Nordisk Launches Daily Weight-Loss Pill to Expand GLP-1 Access TUESDAY, Jan. 6, 2026 (HealthDay News) — A daily pill for weight loss has officially arrived in the U.S. On Monday, Novo Nordisk ...

Both companies are also expanding beyond obesity into adjacent conditions, which could reinforce the long-term investment case. Wegovy remains the only GLP-1 drug proven to reduce heart attacks and ...

The Trump administration has unveiled yet another new payment model, this one focused on the cost of GLP-1 therapies. The Centers for Medicare & Medicaid Services (CMS) on Tuesday announced the Better ...

Dec 23 (Reuters) - The U.S. Centers for Medicare and Medicaid Services on Tuesday unveiled a voluntary program to cover GLP-1 drugs for weight-loss and diabetes under Medicaid and Medicare Part D ...